We are excited to invite you to the 20th Annual International Conference of the Metabolomics Society which will take place from June 16 - 20, 2024 at the ATC Hall in Osaka, Japan.
Don't forget to visit our booth # P2 to discover how Bruker is empowering discoveries through metabolomics and phenomics innovation.
Please join Bruker’s Lunch seminar at 12:20 on June 19!
Mass spectrometry-based untargeted metabolomics is constantly challenged by large-scale and unambiguous metabolite annotation in complex biological matrices, due to the enormous chemical and compositional diversity of metabolome. Zheng-Jiang Zhu, Ph.D. will introduce the metabolic reaction network-based strategy, namely MetDNA, developed in my group for metabolite annotation. The recent version of MetDNA2 employed the knowledge-guided multi-layer networking, to enable global metabolite annotation from knowns to unknowns in untargeted metabolomics. Further, Zheng-Jiang Zhu, Ph.D. will present the expansion of ion mobility separation derived collision cross-section (CCS) to support multidimensional metabolite annotation. All of these technologies facilitate expanding the chemical coverage of annotation and extending the assessment of metabolic pathways and activities.
Zheng-Jiang Zhu, Ph.D., Principal Investigator, Director of Metabolomics Research Center, Interdisciplinary Research Center on Biology and Chemistry (IRCBC), Shanghai Institute of Organic Chemistry (SIOC), Chinese Academy of Sciences, Shanghai, China
NMR-based metabolomics is a pivotal omics tool in biomedical and clinical research, facilitating disease investigation with remarkable versatility. Through diverse application examples from cardiovascular disease, personalized nutrition and cancer research, Claire Cannet will demonstrate NMR’s capability to comprehensively detect and quantify metabolites, even in untargeted approaches, elucidating crucial molecular mechanisms underlying health and disease. Emphasizing standardization, reproducibility, and accuracy, particularly in clinical research, we will explore the significance of these factors in ensuring robust findings. Additionally, Claire Cannet will present new developments in NMR-based metabolomics, spanning from high field NMR to benchtop solutions. These advancements unlock pathways to transformative research and translational success, promising enhanced insights and applications in disease research and therapeutic interventions. Join us for an illuminating discussion on the evolving landscape of NMR-based metabolomics and its profound impact on biomedical and clinical research.
Claire Cannet, Bruker Market Manager Clinical, Bruker BioSpin GmbH, Germany
For Research Use Only. Not for use in clinical diagnostic procedures.